Irritation of the application site is very common. The various types of irritation include redness, scaling, crusting, pain, severe itching, and sometimes infection. Additional possible side effects include eye irritation, such as periorbital edema (3% of patients in studies), headaches (2%) and nasopharyngitis (running nose, 2%). Allergic reactions, shingles, changes in pigmentation at application site, chemical conjunctivitis, and corneal burns may also occur. The European Medicines Agency recommended suspending the marketing authorisation of<unk>  due to concerns regarding increased incidence of skin cancer in patients treated with topical<unk>  compared to vehicle or imiquimod. Physicians were advised to refrain from prescribing<unk>  and to use different treatment options. Subsequently, the marketing authorization holder requested withdrawal of the manufacturing authorization for commercial reasons. The withdrawal was granted and therefore,<unk>  is no longer registered in the EU. Euphorbia peplus
Ingenol mebutate
Nandrolone furylpropionate
Gestonorone caproate
Quingestanol acetate
Segesterone acetate
Dienogest
Degarelix
Bisoctrizole